[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613709":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":21,"locations":22,"responsibleParty":44,"collaborators":21,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":21,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":21,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":21,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Ohio State University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Dasatinib and quercetin",[13],"Drug: Dasatinib and quercetin",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants will receive 100 mg of dasatinib and 1250 mg of quercetin orally once a day for 2 days every 2 weeks over 12 consecutive weeks",[9],[20],"D+Q",null,[23],{"facility":24,"status":21,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Ohio State Martha Morehouse Outpatient Care","Columbus","Ohio","43210","United States","US",{"type":31,"coordinates":32},"Point",[33,34],-82.99879,39.96118,{"lat":34,"lon":33},[37,42],{"name":38,"role":39,"phone":40,"phoneExt":21,"email":41},"Yinan Zhang, MD","CONTACT","614-293-4969","msresearch@osumc.edu",{"name":21,"role":39,"phone":43,"phoneExt":21,"email":21},"6142934969",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Yinan Zhang","Assistant Professor","100613709","phase-1-senolytics-for-secondary-progressive-ms-100613709",false,"NCT07270120","Senolytics for Secondary Progressive MS","Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis","Inclusion Criteria:\n\n1. Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria\n2. Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone.\n3. Evidence of MS progression over the past 12 months.\n\nExclusion Criteria:\n\n1. Unstable coronary artery disease (myocardial infarction within 6 months or angina)\n2. Hospitalization within 6 months\n3. Stroke or transient ischemic attack in the past 6 months\n4. Pulmonary arterial hypertension\n5. Current or chronic history of liver disease\n6. Alzheimer's or Parkinson's disease\n7. Drug or alcohol abuse in the previous 5 years\n8. History of coagulation disorders, central nervous system hemorrhage, or gastrointestinal hemorrhage\n9. History of angina or myocardial infarction, arrhythmia, or heart failure at any time\n10. QTc prolongation\n11. Anemia (Hgb\\\u003C9), thrombocytopenia (platelets\\\u003C50,000 per microliter), or neutropenia (ANC\\\u003C 1000 per microliter)\n12. Moderate hypokalemia (2.9 mmol\u002FL) and moderate hypomagnesemia (0.9-1.1 mg\u002FdL or 0.37-0.45 mmol\u002FL)\n13. ALT\u002FAST \\>1.5x ULN, total bilirubin \\>ULN, and alkaline phosphatase \\>2x ULN\n14. Chronic renal disease (glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2)\n15. Alcohol intake greater than 2 drinks\u002Fday for men and greater than 1 drink\u002Fday for women\n16. Anti-arrhythmic medications known to cause QTc prolongation\n17. Antipsychotics and anxiolytics\n18. Anti-platelet or anti-coagulant medications other than aspirin\n19. Quinolone antibiotics\n20. Pregnant or lactating subjects or subjects intending to become pregnant or to donate egg\u002Fsperm\n21. Participants with p16INK4a below the median of SPMS patients in the OSU Aging and MS Cohort\n22. Use of drugs metabolized by the same liver enzymes as D or Q","ALL","50 Years","85 Years",{"count":59,"type":60},30,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.",[66],"Multiple Sclerosis (MS) Secondary Progressive",[68,69],"senolytic","multiple sclerosis","NOT_YET_RECRUITING","2025-12-04",{"date":73,"type":74},"2025-12-08","ACTUAL",{"date":76,"type":60},"2026-01-15",{"date":78,"type":60},"2028-01-15",{"name":5,"class":6},1]